Fig. 2From: Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)Kaplan-Meier survival curves by treatment arm in patients with MSI-H/dMMR or EBV-positive tumors. (A) Progression-free survival (PFS) and (B) Overall survival (OS). (ICI, immune checkpoint inhibitor; HR, hazard ratio; CI, confidence interval)Back to article page